{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T16:20:45Z","timestamp":1774974045757,"version":"3.50.1"},"reference-count":72,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,5,31]],"date-time":"2024-05-31T00:00:00Z","timestamp":1717113600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004000","name":"Guangzhou Municipal Science and Technology Program key projects","doi-asserted-by":"publisher","award":["202206010106"],"award-info":[{"award-number":["202206010106"]}],"id":[{"id":"10.13039\/501100004000","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004000","name":"Guangzhou Municipal Science and Technology Program key projects","doi-asserted-by":"publisher","award":["2023A04J1921"],"award-info":[{"award-number":["2023A04J1921"]}],"id":[{"id":"10.13039\/501100004000","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82071974"],"award-info":[{"award-number":["82071974"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82371998"],"award-info":[{"award-number":["82371998"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82102107"],"award-info":[{"award-number":["82102107"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012245","name":"Science and Technology Planning Project of Guangdong Province","doi-asserted-by":"publisher","award":["2022A0505050042"],"award-info":[{"award-number":["2022A0505050042"]}],"id":[{"id":"10.13039\/501100012245","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Acta Pharmaceutica Sinica B"],"published-print":{"date-parts":[[2024,9]]},"DOI":"10.1016\/j.apsb.2024.05.033","type":"journal-article","created":{"date-parts":[[2024,6,3]],"date-time":"2024-06-03T16:25:42Z","timestamp":1717431942000},"page":"4014-4027","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["Discovery and evaluation of a novel 18F-labeled vasopressin 1a receptor PET ligand with peripheral binding specificity"],"prefix":"10.1016","volume":"14","author":[{"given":"Junqi","family":"Hu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8864-1712","authenticated-orcid":false,"given":"Yinlong","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chenchen","family":"Dong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Huiyi","family":"Wei","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kai","family":"Liao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Junjie","family":"Wei","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chunyu","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-0614-3335","authenticated-orcid":false,"given":"Ahmad","family":"Chaudhary","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jiahui","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hao","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ke","family":"Zhong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Steven H.","family":"Liang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lu","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0457-3565","authenticated-orcid":false,"given":"Weijian","family":"Ye","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.apsb.2024.05.033_bib1","doi-asserted-by":"crossref","first-page":"89","DOI":"10.3390\/biomedicines9010089","article-title":"The biology of vasopressin","volume":"9","author":"Sparapani","year":"2021","journal-title":"Biomedicines"},{"key":"10.1016\/j.apsb.2024.05.033_bib2","doi-asserted-by":"crossref","DOI":"10.1210\/endocr\/bqab082","article-title":"Cardiovascular neuroendocrinology: emerging role for neurohypophyseal hormones in pathophysiology","volume":"162","author":"Aikins","year":"2021","journal-title":"Endocrinology"},{"key":"10.1016\/j.apsb.2024.05.033_bib3","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1152\/physrev.00035.2011","article-title":"Vasopressin V1a and V1b receptors: from molecules to physiological systems","volume":"92","author":"Koshimizu","year":"2012","journal-title":"Physiol Rev"},{"key":"10.1016\/j.apsb.2024.05.033_bib4","doi-asserted-by":"crossref","first-page":"7807","DOI":"10.1073\/pnas.0600875103","article-title":"V1a vasopressin receptors maintain normal blood pressure by regulating circulating blood volume and baroreflex sensitivity","volume":"103","author":"Koshimizu","year":"2006","journal-title":"Proc Natl Acad Sci U\u00a0S\u00a0A"},{"key":"10.1016\/j.apsb.2024.05.033_bib5","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1007\/s10157-011-0497-y","article-title":"The roles of V1a vasopressin receptors in blood pressure homeostasis: a review of studies on V1a receptor knockout mice","volume":"16","author":"Fujiwara","year":"2011","journal-title":"Clin Exp Nephrol"},{"key":"10.1016\/j.apsb.2024.05.033_bib6","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1002\/hep.28250","article-title":"Vasopressin 1a receptor partial agonism increases sodium excretion and reduces portal hypertension and ascites in cirrhotic rats","volume":"63","author":"Fern\u00e1ndez-Varo","year":"2015","journal-title":"Hepatology"},{"key":"10.1016\/j.apsb.2024.05.033_bib7","first-page":"500","article-title":"Association of variants of arginine vasopressin and arginine vasopressin receptor 1a with severe acetaminophen liver injury","volume":"3","author":"Randesi","year":"2017","journal-title":"Cell Mol Gastroenter"},{"key":"10.1016\/j.apsb.2024.05.033_bib8","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aaw4636","article-title":"Arginine vasopressin receptor 1a is a therapeutic target for castration-resistant prostate cancer","volume":"11","author":"Zhao","year":"2019","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.apsb.2024.05.033_bib9","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.jclinane.2017.04.017","article-title":"Vasoplegic syndrome: an update on perioperative considerations","volume":"40","author":"Liu","year":"2017","journal-title":"J Clin Anesth"},{"key":"10.1016\/j.apsb.2024.05.033_bib10","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2023.115116","article-title":"Partial vasopressin 1a receptor agonism reduces portal hypertension and hyperaldosteronism and induces a powerful diuretic and natriuretic effect in rats with cirrhosis and ascites","volume":"165","author":"Fern\u00e1ndez-Varo","year":"2023","journal-title":"Biomed Pharmacother"},{"key":"10.1016\/j.apsb.2024.05.033_bib11","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1016\/j.conb.2004.03.009","article-title":"Neuroendocrine basis of social recognition","volume":"14","author":"Winslow","year":"2004","journal-title":"Curr Opin Neurobiol"},{"key":"10.1016\/j.apsb.2024.05.033_bib12","doi-asserted-by":"crossref","first-page":"1442","DOI":"10.1089\/neu.2012.2807","article-title":"Arginine vasopressin V1a receptor-deficient mice have reduced brain edema and secondary brain damage following traumatic brain injury","volume":"30","author":"Rauen","year":"2013","journal-title":"J Neurotrauma"},{"key":"10.1016\/j.apsb.2024.05.033_bib13","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.yfrne.2015.04.003","article-title":"Vasopressin and oxytocin receptor systems in the brain: sex differences and sex-specific regulation of social behavior","volume":"40","author":"Dumais","year":"2016","journal-title":"Front Neuroendocrinol"},{"key":"10.1016\/j.apsb.2024.05.033_bib14","doi-asserted-by":"crossref","first-page":"e1174","DOI":"10.1038\/tp.2017.121","article-title":"Arginine vasopressin ameliorates spatial learning impairments in chronic cerebral hypoperfusion via V1a receptor and autophagy signaling partially","volume":"7","author":"Yang","year":"2017","journal-title":"Transl Psychiat"},{"key":"10.1016\/j.apsb.2024.05.033_bib15","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1007\/BF00518192","article-title":"Modulation of social memory in male rats by neurohypophyseal peptides","volume":"91","author":"Dantzer","year":"1987","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.apsb.2024.05.033_bib16","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/S0166-4328(98)00004-7","article-title":"Differential modulation of lateral septal vasopressin receptor blockade in spatial learning, social recognition, and anxiety-related behaviors in rats","volume":"99","author":"Everts","year":"1999","journal-title":"Behav Brain Res"},{"key":"10.1016\/j.apsb.2024.05.033_bib17","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/0031-9384(94)90022-1","article-title":"Microdialysis administration of vasopressin into the septum improves social recognition in Brattleboro rats","volume":"55","author":"Engelmann","year":"1994","journal-title":"Physiol Behav"},{"key":"10.1016\/j.apsb.2024.05.033_bib18","doi-asserted-by":"crossref","first-page":"4250","DOI":"10.1523\/JNEUROSCI.15-06-04250.1995","article-title":"V1 vasopressin receptor antisense oligodeoxynucleotide into septum reduces vasopressin binding, social discrimination abilities, and anxiety-related behavior in rats","volume":"15","author":"Landgraf","year":"1995","journal-title":"J Neurosci"},{"key":"10.1016\/j.apsb.2024.05.033_bib19","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1111\/j.1601-183X.2005.00119.x","article-title":"Association of vasopressin 1a receptor levels with a regulatory microsatellite and behavior","volume":"4","author":"Hammock","year":"2005","journal-title":"Genes Brain Behav"},{"key":"10.1016\/j.apsb.2024.05.033_bib20","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1016\/j.neuron.2005.06.031","article-title":"The V1a vasopressin receptor is necessary and sufficient for normal social recognition: a gene replacement study","volume":"47","author":"Bielsky","year":"2005","journal-title":"Neuron"},{"key":"10.1016\/j.apsb.2024.05.033_bib21","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.yhbeh.2011.10.002","article-title":"Vasopressin regulates social recognition in juvenile and adult rats of both sexes, but in sex- and age-specific ways","volume":"61","author":"Veenema","year":"2012","journal-title":"Horm Behav"},{"key":"10.1016\/j.apsb.2024.05.033_bib22","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1038\/sj.mp.4001125","article-title":"Transmission disequilibrium testing of arginine vasopressin receptor 1A (AVPR1A) polymorphisms in autism","volume":"7","author":"Kim","year":"2002","journal-title":"Mol Psychiatry"},{"key":"10.1016\/j.apsb.2024.05.033_bib23","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1038\/sj.mp.4001812","article-title":"Association between the arginine vasopressin 1a receptor (AVPR1a) gene and autism in a family-based study: mediation by socialization skills","volume":"11","author":"Yirmiya","year":"2006","journal-title":"Mol Psychiatry"},{"key":"10.1016\/j.apsb.2024.05.033_bib24","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/j.psychres.2009.11.007","article-title":"Family-based association study of microsatellites in the 5\u2032 flanking region of AVPR1A with autism spectrum disorder in the Korean population","volume":"178","author":"Yang","year":"2010","journal-title":"Psychiatry Res"},{"key":"10.1016\/j.apsb.2024.05.033_bib25","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/2040-2392-2-3","article-title":"Functionality of promoter microsatellites of arginine vasopressin receptor 1A (AVPR1A): implications for autism","volume":"2","author":"Tansey","year":"2011","journal-title":"Mol Autism"},{"key":"10.1016\/j.apsb.2024.05.033_bib26","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1038\/nrn3044","article-title":"Oxytocin and vasopressin in the human brain: social neuropeptides for translational medicine","volume":"12","author":"Meyer-Lindenberg","year":"2011","journal-title":"Nat Rev Neurosci"},{"key":"10.1016\/j.apsb.2024.05.033_bib27","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1038\/sj.npp.1300360","article-title":"Profound impairment in social recognition and reduction in anxiety-like behavior in vasopressin V1a receptor knockout mice","volume":"29","author":"Bielsky","year":"2003","journal-title":"Neuropsychopharmacol"},{"key":"10.1016\/j.apsb.2024.05.033_bib28","article-title":"Gestational valproate alters BOLD activation in response to complex social and primary sensory stimuli","volume":"7","author":"Sakakibara","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.apsb.2024.05.033_bib29","doi-asserted-by":"crossref","first-page":"1914","DOI":"10.1038\/npp.2016.232","article-title":"A single dose, randomized, controlled proof-of-mechanism study of a novel vasopressin 1a receptor antagonist (RG7713) in high-functioning adults with autism spectrum disorder","volume":"42","author":"Umbricht","year":"2016","journal-title":"Neuropsychopharmacol"},{"key":"10.1016\/j.apsb.2024.05.033_bib30","doi-asserted-by":"crossref","first-page":"1843","DOI":"10.1002\/aur.2550","article-title":"Early social rearing, the V1A arginine vasopressin receptor genotype, and autistic traits in chimpanzees","volume":"14","author":"Weiss","year":"2021","journal-title":"Autism Res"},{"key":"10.1016\/j.apsb.2024.05.033_bib31","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1002\/jdn.10297","article-title":"Efficacy and safety of V1a receptor antagonists in autism spectrum disorder: a meta-analysis","volume":"84","author":"Kimi","year":"2023","journal-title":"Int J Dev Neurosci"},{"key":"10.1016\/j.apsb.2024.05.033_bib32","doi-asserted-by":"crossref","first-page":"2603","DOI":"10.3390\/biomedicines11102603","article-title":"Vasopressin as possible treatment option in autism spectrum disorder","volume":"11","author":"L\u00e1szl\u00f3","year":"2023","journal-title":"Biomedicines"},{"key":"10.1016\/j.apsb.2024.05.033_bib33","doi-asserted-by":"crossref","first-page":"3068","DOI":"10.3390\/ijms23063068","article-title":"Vasopressin and its analogues: from natural hormones to multitasking peptides","volume":"23","author":"Glava\u0161","year":"2022","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.apsb.2024.05.033_bib34","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1080\/13543776.2023.2218546","article-title":"Vasopressin receptor antagonists: a patent summary (2018\u20122022)","volume":"33","author":"Baska","year":"2023","journal-title":"Expert Opin Ther Pat"},{"key":"10.1016\/j.apsb.2024.05.033_bib35","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1126\/science.1850553","article-title":"OPC-21268, an orally effective, nonpeptide vasopressin V1 receptor antagonist","volume":"252","author":"Yamamura","year":"1991","journal-title":"Science"},{"key":"10.1016\/j.apsb.2024.05.033_bib36","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1172\/JCI116554","article-title":"Biochemical and pharmacological properties of SR 49059, a new, potent, nonpeptide antagonist of rat and human vasopressin V1a receptors","volume":"92","author":"Serradeil-Le Gal","year":"1993","journal-title":"J Clin Investig"},{"key":"10.1016\/j.apsb.2024.05.033_bib37","doi-asserted-by":"crossref","first-page":"2033","DOI":"10.1002\/jps.23495","article-title":"Pharmacokinetics and metabolism of SRX246: a potent and selective vasopressin 1a antagonist","volume":"102","author":"Fabio","year":"2013","journal-title":"J Pharm Sci"},{"key":"10.1016\/j.apsb.2024.05.033_bib38","doi-asserted-by":"crossref","first-page":"3682","DOI":"10.3390\/jcm9113682","article-title":"Safety and tolerability of SRX246, a vasopressin 1a antagonist, in irritable huntington's disease patients\u2014a randomized phase 2 clinical trial","volume":"9","author":"Brownstein","year":"2020","journal-title":"J Clin Med"},{"key":"10.1016\/j.apsb.2024.05.033_bib39","doi-asserted-by":"crossref","first-page":"2393","DOI":"10.1007\/s00213-021-05861-4","article-title":"The novel vasopressin receptor (V1aR) antagonist SRX246 reduces anxiety in an experimental model in humans: a randomized proof-of-concept study","volume":"238","author":"Lago","year":"2021","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.apsb.2024.05.033_bib40","doi-asserted-by":"crossref","first-page":"1561","DOI":"10.3390\/jpm12101561","article-title":"The vasopressin 1a receptor antagonist SRX246 reduces aggressive behavior in Huntington's disease","volume":"12","author":"Maibach","year":"2022","journal-title":"J Pers Med"},{"key":"10.1016\/j.apsb.2024.05.033_bib41","doi-asserted-by":"crossref","first-page":"2275","DOI":"10.1021\/jm501745f","article-title":"Discovery of highly selective brain-penetrant vasopressin 1a antagonists for the potential treatment of autism via a chemogenomic and scaffold hopping approach","volume":"58","author":"Ratni","year":"2015","journal-title":"J Med Chem"},{"key":"10.1016\/j.apsb.2024.05.033_bib42","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.1021\/acs.jmedchem.9b01478","article-title":"Discovery of balovaptan, a vasopressin 1a receptor antagonist for the treatment of autism spectrum disorder","volume":"63","author":"Schnider","year":"2020","journal-title":"J Med Chem"},{"key":"10.1016\/j.apsb.2024.05.033_bib43","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aat7838","article-title":"A phase 2 clinical trial of a vasopressin V1a receptor antagonist shows improved adaptive behaviors in men with autism spectrum disorder","volume":"11","author":"Bolognani","year":"2019","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.apsb.2024.05.033_bib44","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1001\/jamapsychiatry.2022.1717","article-title":"Balovaptan vs placebo for social communication in childhood autism spectrum disorder","volume":"79","author":"Hollander","year":"2022","journal-title":"JAMA Psychiatry"},{"key":"10.1016\/j.apsb.2024.05.033_bib45","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/S2215-0366(21)00429-6","article-title":"Efficacy and safety of balovaptan for socialisation and communication difficulties in autistic adults in North America and Europe: a phase 3, randomised, placebo-controlled trial","volume":"9","author":"Jacob","year":"2022","journal-title":"Lancet Psychiat"},{"key":"10.1016\/j.apsb.2024.05.033_bib46","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.1016\/j.bmc.2011.12.013","article-title":"Synthesis and evaluation of potent and selective human V1a receptor antagonists as potential ligands for PET or SPECT imaging","volume":"20","author":"Fabio","year":"2012","journal-title":"Bioorg Med Chem"},{"key":"10.1016\/j.apsb.2024.05.033_bib47","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1016\/j.ejmech.2017.08.037","article-title":"Development of a radioligand for imaging V1a vasopressin receptors with PET","volume":"139","author":"Naik","year":"2017","journal-title":"Eur J Med Chem"},{"key":"10.1016\/j.apsb.2024.05.033_bib48","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2021.105886","article-title":"Development of a triazolobenzodiazepine-based PET probe for subtype-selective vasopressin 1A receptor imaging","volume":"173","author":"Haider","year":"2021","journal-title":"Pharmacol Res"},{"key":"10.1016\/j.apsb.2024.05.033_bib49","doi-asserted-by":"crossref","first-page":"3257","DOI":"10.1038\/s41467-023-36377-4","article-title":"Radiochemistry for positron emission tomography","volume":"14","author":"Rong","year":"2023","journal-title":"Nat Commun"},{"key":"10.1016\/j.apsb.2024.05.033_bib50","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1016\/j.ddtec.2004.11.014","article-title":"Prediction of blood\u2013brain barrier permeation in drug discovery from in\u00a0vivo, in\u00a0vitro and in silico models","volume":"1","author":"Abbott","year":"2004","journal-title":"Drug Discov Today Technol"},{"key":"10.1016\/j.apsb.2024.05.033_bib51","first-page":"16","article-title":"Influence of logBB cut-off on the prediction of blood\u2012brain barrier permeability","volume":"1","author":"Kunwittaya","year":"2013","journal-title":"Biomed Appl Technol J"},{"key":"10.1016\/j.apsb.2024.05.033_bib52","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1021\/cn100008c","article-title":"Moving beyond rules: the development of a central nervous system multiparameter optimization (CNS MPO) approach to enable alignment of druglike properties","volume":"1","author":"Wager","year":"2010","journal-title":"ACS Chem Neurosci"},{"key":"10.1016\/j.apsb.2024.05.033_bib53","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1016\/S1734-1140(10)70357-1","article-title":"Quantification of metformin by the HPLC method in brain regions, cerebrospinal fluid and plasma of rats treated with lipopolysaccharide","volume":"62","author":"\u0141abuzek","year":"2010","journal-title":"Pharmacol Rep"},{"key":"10.1016\/j.apsb.2024.05.033_bib54","doi-asserted-by":"crossref","first-page":"2580","DOI":"10.1002\/anie.201805501","article-title":"Chemistry for positron emission tomography: recent advances in 11C-, 18F-, 13N-, and 15O-labeling reactions","volume":"58","author":"Deng","year":"2019","journal-title":"Angew Chem Int Ed"},{"key":"10.1016\/j.apsb.2024.05.033_bib55","doi-asserted-by":"crossref","first-page":"1953","DOI":"10.1016\/0024-3205(92)90524-S","article-title":"Radioligand binding studies reveal marked species differences in the vasopressin V1 receptor of rat, rhesus and human tissues","volume":"50","author":"Pettibone","year":"1992","journal-title":"Life Sci"},{"key":"10.1016\/j.apsb.2024.05.033_bib56","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1038\/ki.1996.341","article-title":"Autoradiographic localization of vasopressin V1a receptors in the rat kidney using [3H]-SR 49059","volume":"50","author":"Gal","year":"1996","journal-title":"Kidney Int"},{"key":"10.1016\/j.apsb.2024.05.033_bib57","doi-asserted-by":"crossref","first-page":"F997","DOI":"10.1152\/ajprenal.00399.2003","article-title":"Age-dependent regulation of vasopressin V1a receptors in preglomerular vessels from the spontaneously hypertensive rat","volume":"286","author":"V\u00e5gnes","year":"2004","journal-title":"Am J Physiol-renal"},{"key":"10.1016\/j.apsb.2024.05.033_bib58","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1007\/s00429-016-1260-7","article-title":"Age and sex differences in oxytocin and vasopressin V1a receptor binding densities in the rat brain: focus on the social decision-making network","volume":"222","author":"Smith","year":"2016","journal-title":"Brain Struct Funct"},{"key":"10.1016\/j.apsb.2024.05.033_bib59","first-page":"2195","article-title":"Vasopressin receptors in human adrenal medulla and pheochromocytoma1","volume":"84","author":"Grazzini","year":"1999","journal-title":"J Clin Endocr Metab"},{"key":"10.1016\/j.apsb.2024.05.033_bib60","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1111\/j.1471-4159.2011.07208.x","article-title":"Quantitative targeted absolute proteomics of human blood\u2013brain barrier transporters and receptors","volume":"117","author":"Uchida","year":"2011","journal-title":"J Neurochem"},{"key":"10.1016\/j.apsb.2024.05.033_bib61","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2023.106681","article-title":"Quantitative assessment of translocator protein (TSPO) in the non-human primate brain and clinical translation of [18F]LW223 as a TSPO-targeted PET radioligand","volume":"189","author":"Tan","year":"2023","journal-title":"Pharmacol Res"},{"key":"10.1016\/j.apsb.2024.05.033_bib62","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.2967\/jnumed.116.184481","article-title":"Validation of the semiquantitative static suvr method for 18F-AV45 PET by pharmacokinetic modeling with an arterial input function","volume":"58","author":"Ottoy","year":"2017","journal-title":"J Nucl Med"},{"key":"10.1016\/j.apsb.2024.05.033_bib63","doi-asserted-by":"crossref","first-page":"2962","DOI":"10.1007\/s00259-023-06270-9","article-title":"In\u00a0vivo evaluation of a novel 18F-labeled PET radioligand for translocator protein 18 kDa (TSPO) in monkey brain","volume":"50","author":"Yan","year":"2023","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.apsb.2024.05.033_bib64","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1016\/j.biopsych.2011.02.023","article-title":"The AVPR1A gene and substance use disorders: association, replication, and functional evidence","volume":"70","author":"Maher","year":"2011","journal-title":"Biol Psychiatry"},{"key":"10.1016\/j.apsb.2024.05.033_bib65","doi-asserted-by":"crossref","first-page":"230","DOI":"10.3389\/fnhum.2019.00230","article-title":"Association of polymorphism of arginine-vasopressin receptor 1a (AVPR1a) gene with trust and reciprocity","volume":"13","author":"Nishina","year":"2019","journal-title":"Front Hum Neurosci"},{"key":"10.1016\/j.apsb.2024.05.033_bib66","article-title":"Association between arginine vasopressin receptor 1A (AVPR1A) polymorphism and inequity aversion","volume":"290","author":"Tanaka","year":"2023","journal-title":"Proc Biol Sci"},{"key":"10.1016\/j.apsb.2024.05.033_bib67","doi-asserted-by":"crossref","first-page":"3099","DOI":"10.1016\/0006-2952(73)90196-2","article-title":"Relationship between the inhibition constant (KI) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction","volume":"22","author":"Yung-Chi","year":"1973","journal-title":"Biochem Pharmacol"},{"key":"10.1016\/j.apsb.2024.05.033_bib68","doi-asserted-by":"crossref","first-page":"1298","DOI":"10.1002\/jps.23901","article-title":"Establishment of optimized MDCK cell lines for reliable efflux transport studies","volume":"103","author":"Gartzke","year":"2014","journal-title":"J Pharm Sci"},{"key":"10.1016\/j.apsb.2024.05.033_bib69","doi-asserted-by":"crossref","first-page":"2468","DOI":"10.1007\/s11095-012-0776-7","article-title":"Discrepancies in the P-glycoprotein-mediated transport of 18F-MPPF: a pharmacokinetic study in mice and non-human primates","volume":"29","author":"Tournier","year":"2012","journal-title":"Pharm Res"},{"key":"10.1016\/j.apsb.2024.05.033_bib70","doi-asserted-by":"crossref","first-page":"1660","DOI":"10.1016\/j.apsb.2022.09.009","article-title":"Ultrasmall, elementary and highly translational nanoparticle X-ray contrast media from amphiphilic iodinated statistical copolymers","volume":"13","author":"Su","year":"2023","journal-title":"Acta Pharm Sin B"},{"key":"10.1016\/j.apsb.2024.05.033_bib71","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.neuroimage.2008.10.058","article-title":"A population-average MRI-based atlas collection\u00a0of the Rhesus macaque","volume":"45","author":"McLaren","year":"2009","journal-title":"Neuroimage"},{"key":"10.1016\/j.apsb.2024.05.033_bib72","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1109\/TAC.1974.1100705","article-title":"A new look at the statistical model identification","volume":"19","author":"Akaike","year":"1974","journal-title":"IEEE Trans Automat Control"}],"container-title":["Acta Pharmaceutica Sinica B"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211383524002296?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211383524002296?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,9,6]],"date-time":"2024-09-06T20:57:43Z","timestamp":1725656263000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2211383524002296"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9]]},"references-count":72,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2024,9]]}},"alternative-id":["S2211383524002296"],"URL":"https:\/\/doi.org\/10.1016\/j.apsb.2024.05.033","relation":{},"ISSN":["2211-3835"],"issn-type":[{"value":"2211-3835","type":"print"}],"subject":[],"published":{"date-parts":[[2024,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Discovery and evaluation of a novel 18F-labeled vasopressin 1a receptor PET ligand with peripheral binding specificity","name":"articletitle","label":"Article Title"},{"value":"Acta Pharmaceutica Sinica B","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.apsb.2024.05.033","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier B.V. on behalf of Chinese Pharmaceutical Association and Institute of Materia Medica, Chinese Academy of Medical Sciences.","name":"copyright","label":"Copyright"}]}}